Summary of Key Points Core Viewpoint - Jimin Health (603222.SH) has announced a share buyback program, indicating a strategic move to enhance shareholder value through repurchasing shares in the market [1] Group 1: Share Buyback Details - As of January 30, 2026, the company has repurchased a total of 5,340,280 shares, which represents 1.02% of the company's total share capital [1] - The highest purchase price for the shares was 9.75 yuan per share, while the lowest was 5.87 yuan per share [1] - The total amount spent on the buyback, excluding transaction fees, is 42,085,552.3 yuan [1]

证券代码：603222 证券简称：济民健康 公告编号：2026-004 济民健康管理股份有限公司(以下简称"公司")于 2025 年 3 月 28 日召开第 五届董事会第十七次会议，审议通过了《关于以集中竞价交易方式回购股份方案 的议案》，同意公司使用自有资金及金融机构借款以集中竞价交易方式回购公司股 份，回购价格不超过人民币 10 元/股（含）；回购资金总额不低于人民币 10,000 万元（含）且不超过人民币 20,000 万元（含）；回购期限为自董事会审议通过回 购方案之日起不超过 12 个月。具体内容详见公司于 2025 年 3 月 29 日在上海证券 交易所网站披露的《公司关于以集中竞价交易方式回购股份的预案》（公告编号： 2025-008）。 二、回购股份的进展情况 根据《上市公司回购股份规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，上市公司应当在回购股份占上市公司总股本的比 例每增加 1%的事实发生之日起 3 日内予以公告。现将公司回购股份进展情况公告 如下： 截至 2026 年 1 月 30 日，公司通过集中竞价交易方式累计回购股份 5,340,280 股，占公司 ...

济民健康管理股份有限公司 关于更换签字会计师的公告 证券代码：603222 证券简称：济民健康 公告编号：2026-005 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 济民健康管理股份有限公司（以下简称"公司"）分别于 2025 年 4 月 27 日、 2025 年 5 月 22 日召开第五届董事会第十八次会议、2024 年年度股东大会，审议 通过了《关于公司确认支付2024年度审计报酬及续聘2025年度审计机构的议案》， 同意公司聘任天健会计师事务所（特殊普通合伙）（以下简称"天健会计师事务 所"）为公司 2025 年度财务报表审计和内部控制审计的会计师事务所。具体内 容详见公司于 2025 年 4 月 29 日在上海证券交易所网站（www.sse.com.cn）披露 的《关于续聘会计师事务所的公告》（公告编号：2025-016）。 签字会计师王潮，2017 年开始从事上市公司审计，2021 年 4 月成为中国注 册会计师，2021 年 4 月开始在天健会计师事务所执业。 （二）诚信记录 王潮近三年内未曾因执业行为 ...

Core Viewpoint - Jimin Health (603222) expects a net loss of 210 million to 250 million yuan for 2025, which is an increase compared to the previous year's loss of 59.71 million yuan [1] Financial Performance - The company anticipates a non-recurring net loss of 205 million to 245 million yuan for 2025 [1] - The company has recognized an inventory impairment provision of approximately 37 million yuan for its pre-filled catheter flushing devices and safety syringes [1] Legal and Compliance Issues - Due to the case involving the forgery of company seals by He Qinghong and others, the company has confirmed related losses of approximately 38 million yuan [1] Asset Valuation - The performance of Ezhou Second Hospital is expected to decline in 2025, leading the company to recognize a goodwill impairment provision of approximately 20 million yuan [1] - After this provision, the cumulative impairment recognized will be approximately 136 million yuan, with a remaining book value of about 15.14 million yuan [1]

Core Viewpoint - Jimin Health (603222) expects a net profit loss of between 210 million to 250 million yuan for the fiscal year 2025, indicating an increase in losses compared to the previous year [1] Group 1: Financial Performance - The anticipated net profit loss for 2025 represents a worsening financial situation for the company compared to the same period last year [1] - The company attributes the increased losses to several factors, including the "He Qinghong stamp forging incident," which has further impacted revenue [1] Group 2: Contributing Factors - The financial performance is also affected by the provision for inventory impairment, recognition of losses related to implicated distributors, and the provision for goodwill impairment concerning Ezhou Second Hospital [1]

Core Viewpoint - Jimin Health has announced a projected net loss for the year 2025, indicating a significant increase in losses compared to the previous year [1] Financial Performance - The company expects a net profit attributable to shareholders of the parent company to be between -210 million and -250 million yuan for 2025, which is a deterioration from the previous year's loss of -59.71 million yuan [1] - The projected net profit, excluding non-recurring gains and losses, is anticipated to be between -205 million and -245 million yuan for 2025 [1]

Core Viewpoint - The company Jimin Health (603222) has announced a forecast for a net loss of 210 million to 250 million yuan for the year 2025, compared to a loss of 59.71 million yuan in the previous year [4] Financial Performance - The expected net profit loss for 2025 is between 210 million and 250 million yuan, with a non-recurring net profit loss estimated at 205 million to 245 million yuan, compared to a loss of 58.69 million yuan in the previous year [4] - The company's price-to-book ratio (LF) is approximately 3.55 times, and the price-to-sales ratio (TTM) is about 7.78 times based on the latest closing price [4] Business Impact Factors - The company's revenue has declined further due to factors such as U.S. tariff policies and the "He Qinghong stamp forgery incident," leading to increased losses [15] - The company has made provisions for inventory impairment of approximately 37 million yuan for pre-filled catheter flushing devices and safety syringes [15] - Losses related to the "He Qinghong and others forging company seals" case have been confirmed at around 38 million yuan [15] - The performance of Ezhou Second Hospital has declined compared to the previous year, prompting the company to make a goodwill impairment provision of approximately 20 million yuan [15]

格隆汇1月23日丨济民健康(603222.SH)公布，公司预计2025年度归属于母公司所有者的净利润为-21,000 万元到-25,000万元，与上年同期-5,971.17万元相比，将增加亏损。公司预计2025年度实现归属于母公司 所有者的扣除非经常性损益的净利润为-20,500万元到-24,500万元。报告期内，受美国关税政策和"何清 红私刻印章事件"等因素的影响，公司收入进一步下滑，导致公司亏损进一步增加。 ...

证券代码：603222 证券简称：济民健康 公告编号：2026-003 济民健康管理股份有限公司 重要内容提示： 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 2025 年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 （二）业绩预告情况 1、经济民健康管理股份有限公司（以下简称"公司"）财务部初步测算， 预计 2025 年度归属于母公司所有者的净利润为-21,000 万元到-25,000 万元， 与上年同期-5,971.17 万元相比，将增加亏损。 2、预计 2025 年度实现归属于母公司所有者的扣除非经常性损益后的净利 润为-20,500 万元到-24,500 万元。 （三）本次业绩预告未经注册会计师审计。 二、上年同期经营业绩 （一）归属于母公司所有者的净利润：-5,971.17 万元。归属于母公司所 有者的扣除非经常性损益的净利润：-5,869.18 万元。 （二）每股收益：-0.11 元。 本业绩预告适用于净利润为负值的情形。 公 ...

济民健康公告，预计2025年度归属于母公司所有者的净利润为亏损2.1亿元到2.5亿元，上年同期为亏损 5971.17万元。报告期内，受美国关税政策和"何清红私刻印章事件"等因素的影响，公司收入进一步下 滑，导致公司亏损进一步增加。 ...